Study Description
The primary objective of this non-interventional study is to describe the evolution of
Hidradenitis suppurativa (HS) symptoms 12 months after secukinumab initiation based on
the patients' assessment of pain, oozing, and bad smell. This study is a prospective (primary data), national, descriptive, non-interventional,
multicentre study conducted by medical practice and hospital-based dermatologists across
different geographical regions in France.
This real-world study does not change the physician-patient relationship or patient
management or follow-up. Physicians remain free with their prescriptions and patient
follow-up procedures. In fact, secukinumab initiation and all treatment decisions will be
made according to routine medical care and independently of study participation.
Recruited patients will be longitudinally followed-up for the duration of the study, up
to 24 months (± 3 months) after secukinumab initiation or secukinumab treatment
discontinuation before the end of the 24 months of follow-up (early discontinuation).
Eligibility Criteria
Inclusion Criteria:
1. Male and female patients ≥ 18 years old,
2. Patients who do not object to participation in the study,
3. Diagnosis of HS clinically confirmed,
4. Initiation of secukinumab treatment for HS in compliance with the summary of product
characteristics,
5. The physician's decision to initiate secukinumab has been taken according to his/her
own practice and regardless of study participation.
Exclusion Criteria:
1. Patients with any medical or psychological condition which, in the physician's
opinion, may prevent participation in the study,
2. Patients participating in a clinical trial.
Worldwide Contacts
If the location of your choosing does not feature any contact detail, please reach out using the information below.